Psoriasis treatment drug Bryhali (halobetasol propionate) emulsion launched in US

recently, Bausch Health(and its dermatology company, Ortho Dermatologics) announced the launch of Bryhali (halobetasol propionate, 0.01%) emulsion in the United States, a local treatmentdrug(for the treatment of plaque-type psoriasis in adult patients)Bryhali received(provisional) from the U.SFDA on October 12, 2018 and final approval on November 6, 2018About Bryhali emulsionBryhali emulsion is a new type of powerful corticosteroid hormone drug that contains 0.01% halogenbutibutiproflocinin in the innovative excipient lotionThe safety of Bryhali emulsions has been confirmed in clinical studies, with patients treated with a daily local drug for 8 weeks, showing good tolerance and no increase in epidermis atrophyrelated studiesBryhali emulsion approval is based on data from two prospective, multicenter, randomized double-blind studiesThe study enrolled a total of 430 adult patients aged 18 and over with moderate to severe plaque-type psoriasis2 studies, 37% and 38% of patients in the Bryhali treatment group were successful in treatment (IGA improved at least 2 levels relative to baseline, IGA scored 0 (clear) or 1 (almost clear), and after 8 weeks of treatment there was no increase in skin atrophy, compared with 8% and 12% of patients in the extostrophic group, respectivelyin addition, two studies have shown that Bryhali emulsions showed significant therapeutic success in the second and fourth weeks of topical use (study 1) and 4 weeks (study 2) and continued to 12 weeks (4 weeks after treatment)In terms of safety
the most common adverse reactions observed in patients with Bryhali medication for 8 weeks were upper respiratory tract infections (2%), drug site dermatitis (1%) and high blood sugar (1%) studies have observed the possibility of reversible hypothalamus-pituitary-adrenal (HPA) axial suppression, the possibility of glucocorticoid deficiency during or after treatment of Bryhali emulsion